# ThyGeNEXT

Source: https://onco.cc/drugs/thygenext/  
OnCo record `thygenext` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ThyGeNEXT is a genetic test from Interpace Biosciences, run on a thyroid nodule sample, that looks for the mutations most often found in thyroid cancer.

## Summary

ThyGeNEXT is Interpace Biosciences' oncogene and mRNA fusion panel for indeterminate thyroid nodules, those cytology cannot call benign or malignant. Interpace states the markers inform diagnosis, prognosis and treatment aligned to FDA-approved therapies for RET, NTRK and other alterations. Its result is combined with ThyraMIR v2 to refine the malignancy risk.

## Fields

- Kind: Treatment
- Status: established
- Last checked: 2026-11-04
- Tags: pipeline
- Modality: Thyroid nodule DNA and RNA sequencing panel (oncogenes and fusions)
- Mechanism: A next-generation DNA and RNA sequencing panel of the commonest thyroid cancer mutations and mRNA fusions, including RET and NTRK, whose result is combined with the ThyraMIR v2 microRNA test, as described by Interpace Biosciences.

## Sources

- SEC: Interpace Biosciences Form S-1/A, October 2026: https://www.sec.gov/Archives/edgar/data/1054102/000149315226049456/forms-1a.htm

## Connected records

- technologies: [Thyroid nodule FNA, Bethesda cytology & molecular classifiers](https://onco.cc/technologies/thyroid-fna-molecular/)
- drugs: [ThyraMIR v2](https://onco.cc/drugs/thyramir-v2/)
- companies: [Interpace Biosciences](https://onco.cc/companies/interpace-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/thygenext.json